Loading news...
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon's NEXPLANON receives U.S. FDA sNDA approval for extended duration of use up to five years, including data for use in women with varying BMIs.
In the closing of the recent trading day, Organon (OGN) stood at $8.7, denoting a +1.05% move from the preceding trading day.
Organon (OGN) reached $8.61 at the closing of the latest trading day, reflecting a +2.14% change compared to its last close.
Organon and Co. (NYSE: OGN - Get Free Report) has earned a consensus recommendation of "Reduce" from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Four research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a strong buy rating to
Organon and Co. (NYSE: OGN - Get Free Report) and Embecta (NASDAQ: EMBC - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings. Valuation and Earnings This table compares Organon and
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters into agreement to expand access to a new, first-in-class treatment in certain European countries; builds on cardiovascular portfolio.
Organon and Co. (NYSE: OGN - Get Free Report) saw unusually large options trading on Tuesday. Stock investors acquired 17,794 call options on the stock. This is an increase of 550% compared to the average volume of 2,737 call options. Institutional Inflows and Outflows Several institutional investors have recently bought and sold shares of the company.
Organon and Co. (NYSE: OGN - Get Free Report) and Ardent Health (NYSE: ARDT - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk. Institutional and Insider Ownership 77.4% of
Organon (OGN) concluded the recent trading session at $7.44, signifying a +2.76% move from its prior day's close.
Cantor Fitzgerald Investment Advisors L.P. decreased its stake in Organon and Co. (NYSE: OGN) by 65.2% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 41,594 shares of the company's stock after selling 77,769 shares during the period. Cantor
Gilman Hill Asset Management LLC lessened its holdings in shares of Organon and Co. (NYSE: OGN) by 87.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 25,935 shares of the company's stock after selling 177,746 shares during the quarter. Gilman Hill Asset
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In the latest trading session, Organon (OGN) closed at $6.98, marking a +2.2% move from the previous day.
Squarepoint Ops LLC acquired a new stake in Organon and Co. (NYSE: OGN) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 116,502 shares of the company's stock, valued at approximately $1,128,000. A number of other institutional investors have also
VANCOUVER, BC / ACCESS Newswire / December 18, 2025 / (TSXV:OGN)(OTCQB:OGNNF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce an exploration update on the Ermitaño gold mine forming part of the Santa Elena mine complex in Sonora Mexico, operated by First Majestic Silver Corp. ("First Majestic"). 1 Orogen holds a cash-flowing 2% net smelter return ("NSR") royalty on the 167 square-kilometre Ermitaño concession.
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Brandes Investment Partners LP grew its stake in Organon and Co. (NYSE: OGN) by 77.1% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 398,423 shares of the company's stock after acquiring an additional 173,481 shares during the period. Brandes Investment Partners LP owned about
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Creative Planning grew its stake in shares of Organon and Co. (NYSE: OGN) by 109.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 186,614 shares of the company's stock after buying an additional 97,429 shares during the period. Creative